CD3 and CD19

The phrase "CD3 and CD19" refers to two distinct cell surface proteins—CD3, primarily found on T cells, and CD19, primarily found on B cells. These are both well-characterized immunological targets, each with its own molecular and functional identity. The combined mention usually occurs in the context of bispecific antibodies (e.g., blinatumomab) or dual immunotherapy strategies, where CD3 is targeted on T cells and CD19 on B cells for therapeutic purposes, such as redirecting T cell cytotoxicity toward B cells. As a single molecular entity or target, "CD3 and CD19" is an incorrect canonical entry.

Therapeutic approaches involving "CD3 and CD19" typically refer to bispecific agents that engage CD3 on T cells and CD19 on B cells, facilitating T cell-mediated lysis of B cells.